Blacksmith Medicines, Inc.
San Diego, CA Doing business as Forge Therapeutics
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3033 Science Park Rd #270, San Diego, CA 92121, USA
- Website
- blacksmithmedicines.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $1,983,173 |
| FY2025 | $0 |
| FY2024 | $6,265,409 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $1,983,173 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| FG-2101: a first-in-class lpxc inhibitor for the treatment of MDR gramnegative urinary tract infections. | National Institute of Allergy and Infectious Diseases (NIH) | $12,961,082 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Novel small molecule inhibitors of lpxc for multi-drug resistant gram-negative bacteria. | National Institutes of Health | $150,000 |
Similar vendors
About the company
Blacksmith Medicines, Inc. is a biotechnology company that specializes in developing purpose-built medicines targeting human metalloenzymes. They have created a platform that enables efficient research and development of these medicines.
Blacksmith Medicines was awarded a $17.3 million definitive cost-plus-fixed-fee contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop an LPXC inhibitor for the treatment of multidrug-resistant gram-negative urinary tract infections. This work will be performed in San Diego, California over 14 months. There is no set-aside designation associated with this contract.
As a subcontractor, Blacksmith Medicines provides services to develop inhibitors targeting essential metalloenzymes found in high priority Gram-negative bacteria. This includes using their platform of bioinorganic and medicinal chemistry knowledge and proprietary fragment libraries. The goal is to develop a novel LPXC inhibitor for the treatment of lung infections caused by Gram-negative bacteria. The prime contractors were the Trustees of Boston University.
Blacksmith Medicines has not received any prime or sub federal grant awards based on the information provided.
Quick answers
Is Blacksmith Medicines, Inc. registered in SAM.gov?
Yes. Blacksmith Medicines, Inc.'s SAM.gov registration is active through September 25, 2027.
What is Blacksmith Medicines, Inc.'s CAGE code?
Blacksmith Medicines, Inc.'s CAGE code is 6XVV8, and its Unique Entity ID (UEI) is ZCWKWSWHAJD6.
How much has Blacksmith Medicines, Inc. received in federal contracts?
Federal contracts obligated $8,248,582 to Blacksmith Medicines, Inc. in fiscal years 2023 through 2027.
What is Blacksmith Medicines, Inc.'s most recent federal award?
Blacksmith Medicines, Inc.'s most recent federal contract award is FG-2101: a first-in-class lpxc inhibitor for the treatment of MDR gramnegative urinary tract infections (75N93022C00060), from National Institute of Allergy and Infectious Diseases (NIH), on September 21, 2022.
On GovTribe
See Blacksmith Medicines, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors